Max Hodak predicts that Cyens will make first commercial sales of Prima in Europe within weeks of July 2026
“we just, in July, got marketing approval in Europe for Prima to start commercially selling it there. And so that's a major milestone. That means it's it's really commercially available. The first sales will happen in the coming weeks.”
→ Read the source episode
Our resolution criterion
disputableFirst commercial sale of Prima retinal prosthesis occurs in Europe
More from No Priors: Artificial Intelligence | Technology | Startups
Renee Haas predicts that within 5+ years, chip design from idea to GDS2 file will be possible for certain designs, likely using AI tooling.
Renee Haas predicts that semiconductor supply chain constraints will persist for 3-5 years at minimum.
Max Hodak predicts that the next version of Prima will enter human trials within approximately one year and expand addressable patient population to millions
Max Hodak predicts that Cyens' in-house gene therapy will enter human trials within approximately one year
Brian Armstrong predicts New Limit will launch its first phase one clinical trial for epigenetic reprogramming in the next year (2027).
Eric Alabest predicts chess.com will launch additional games beyond chess and poker
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.